Glück Conviction Score™ ⓘ
PHVS
Pharvaris N.V.
⚠
Kein belastbares Signal — erst 31 % der Signal-Gewichte sind mit Daten unterlegt — z. B. junger Filer ohne ausreichende Historie.
Effektiv: Kein belastbares Signal
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
31,8
7 neu, 34 erhöht, 35,2M $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 29.62 | +3.7 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 26.24 | +17.1 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 30.60 | EMA50: 29.66 | |
| MACD-Histogramm | Bullisch | 10 % | 0.096 | Bullisch | |
| RSI(14) | Neutral | 10 % | 52.0 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 46.8 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 17.0 | +DI: 22.4 / −DI: 11.8 | |
| Z-Score(60) | Neutral | 5 % | 0.94 | In Range | |
| 52W-Position | Bullisch | 5 % | 86.4 % | Hoch 32.94 / Tief 16.56 | |
| Bollinger(20,2σ) | Neutral | 5 % | 60.7 % | Upper 32.31 / Mid 30.29 / Lower 28.26 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.0777 | R²=0.66 / annualisiert +67.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-04 | Nijdam Anna | Officer, Principal Accounting Officer | Open Market Sale | -2.670 | 30,87 | -82.425,04 | -40,9% | |
| 2026-05-22 | Nijdam Anna | Officer, Principal Accounting Officer | Open Market Sale | -5.501 | 30,74 | -169.084,24 | -83,8% | |
| 2026-05-21 | Monges Viviane | Director | Open Market Sale | -9.667 | 30,29 | -292.853,06 | -145,1% | |
| 2026-05-21 | Nijdam Anna | Officer, Principal Accounting Officer | Open Market Sale | -1.829 | 30,60 | -55.971,24 | -27,7% | |
| 2026-05-21 | Nassif David W. | Officer, CFO / CLO | Open Market Sale | -10.000 | 30,31 | -303.076,00 | -150,2% | |
| 2026-05-18 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -2.292 | 29,22 | -66.976,82 | -33,2% | |
| 2026-05-15 | Abele Stefan Andreas | Officer, Chief Technical Ops Officer | Open Market Sale | -8.748 | 29,82 | -260.864,49 | -129,3% | |
| 2026-05-15 | Glassman Robert | Director | Open Market Sale | -5.333 | 29,83 | -159.090,86 | -78,9% | |
| 2026-05-15 | Glassman Robert | Director | Open Market Sale | -4.667 | 29,82 | -139.154,54 | -69,0% | |
| 2026-05-15 | Souverijns Wim | Officer, Chief Commercial Officer | Open Market Sale | -10.000 | 29,92 | -299.163,00 | -148,3% | |
| 2026-05-01 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -14.023 | 30,16 | -422.985,57 | -209,6% | |
| 2026-05-01 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -143 | 31,00 | -4.433,00 | -2,2% | |
| 2026-04-30 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -3.700 | 30,26 | -111.946,46 | -55,5% | |
| 2026-04-30 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -670 | 31,03 | -20.791,51 | -10,3% | |
| 2026-04-30 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -28.400 | 30,30 | -860.588,16 | -426,5% | |
| 2026-04-30 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -18.000 | 30,26 | -544.604,40 | -269,9% | |
| 2026-04-30 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -19.200 | 30,26 | -580.909,44 | -287,9% | |
| 2026-04-30 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -15.000 | 30,24 | -453.627,00 | -224,8% | |
| 2026-04-29 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -3.733 | 30,06 | -112.232,27 | -55,6% | |
| 2026-04-29 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -3.700 | 30,06 | -111.229,40 | -55,1% | |
| 2026-04-29 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -3.830 | 30,07 | -115.165,04 | -57,1% | |
| 2026-04-29 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -3.700 | 30,08 | -111.280,46 | -55,2% | |
| 2026-04-23 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -100 | 30,03 | -3.003,00 | -1,5% | |
| 2026-04-23 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -100 | 30,03 | -3.003,00 | -1,5% | |
| 2026-04-23 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -100 | 30,03 | -3.003,00 | -1,5% | |
| 2026-04-23 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -100 | 30,03 | -3.003,00 | -1,5% | |
| 2026-04-22 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -500 | 30,00 | -15.000,00 | -7,4% | |
| 2026-04-22 | Schikan Johannes Gerardus Christiaan Petrus | Director | Open Market Sale | -7.000 | 30,05 | -210.378,70 | -104,3% | |
| 2026-04-22 | Lu Peng | Officer, Chief Medical Officer | Open Market Sale | -7.001 | 30,05 | -210.401,75 | -104,3% | |
| 2026-04-22 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -7.000 | 30,05 | -210.361,90 | -104,3% | |
| 2026-04-22 | Lesage Anne | Officer, Chief Early Development | Open Market Sale | -7.000 | 30,05 | -210.357,70 | -104,3% | |
| 2026-04-16 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -2.292 | 28,60 | -65.558,53 | -32,5% | |
| 2026-04-09 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -23.133 | 27,74 | -641.598,38 | -318,0% | |
| 2026-04-09 | Modig Berndt | Director, Officer, Chief Executive Officer | Open Market Sale | -200 | 28,42 | -5.683,00 | -2,8% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. | 8.031.252 | 8.031.252 | 0 | 226.882.869 | Unverändert | 0,0% | |
| FMR LLC | 6.284.472 | 6.399.158 | -114.686 | 177.536.335 | Reduziert | -1,8% | |
| Foresite Capital Management IV, LLC | 4.778.581 | 4.778.581 | 0 | 134.994.913 | Unverändert | 0,0% | |
| venBio Partners LLC | 4.639.304 | 4.639.304 | 0 | 131.060.338 | Unverändert | 0,0% | |
| VIKING GLOBAL INVESTORS LP | 3.653.310 | 3.653.310 | 0 | 103.206.008 | Unverändert | 0,0% | |
| EQT Fund Management S.a r.l. | 3.424.609 | 3.424.609 | 0 | 96.745.204 | Unverändert | 0,0% | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.126.042 | 3.126.042 | 0 | 88.310.687 | Unverändert | 0,0% | |
| Bain Capital Life Sciences Investors, LLC | 2.675.509 | 2.802.081 | -126.572 | 75.583.129 | Reduziert | -4,5% | |
| WELLINGTON MANAGEMENT GROUP LLP | 2.118.900 | 1.905.793 | 213.107 | 59.858.926 | Aufgestockt | +11,2% | |
| Commodore Capital LP | 1.918.970 | 1.889.445 | 29.525 | 54.210.903 | Aufgestockt | +1,6% | |
| Novo Holdings A/S | 1.750.000 | 1.750.000 | 0 | 49.437.500 | Unverändert | 0,0% | |
| Saturn V Capital Management LP | 1.201.402 | 1.140.033 | 61.369 | 33.939.606 | Aufgestockt | +5,4% | |
| Point72 Asset Management, L.P. | 1.007.016 | 711.625 | 295.391 | 28.448.202 | Aufgestockt | +41,5% | |
| Cormorant Asset Management, LP | 1.000.000 | 1.083.000 | -83.000 | 28.250.000 | Reduziert | -7,7% | |
| Sofinnova Investments, Inc. | 818.328 | 745.169 | 73.159 | 23.117.766 | Aufgestockt | +9,8% | |
| 5AM Venture Management, LLC | 797.600 | 797.600 | 0 | 22.532.200 | Unverändert | 0,0% | |
| Polar Capital Holdings Plc | 781.016 | 237.962 | 543.054 | 22.063.702 | Aufgestockt | +228,2% | |
| BlackRock, Inc. | 757.213 | 708.558 | 48.655 | 21.391.267 | Aufgestockt | +6,9% | |
| Soleus Capital Management, L.P. | 702.052 | 702.052 | 0 | 19.832.969 | Unverändert | 0,0% | |
| Rock Springs Capital Management LP | 645.533 | 623.402 | 22.131 | 18.236.307 | Aufgestockt | +3,6% | |
| Kynam Capital Management, LP | 640.395 | 640.395 | 0 | 18.091.159 | Unverändert | 0,0% | |
| Patient Square Capital LP | 493.000 | 542.696 | -49.696 | 13.927.250 | Reduziert | -9,2% | |
| Ikarian Capital, LLC | 486.856 | 486.856 | 0 | 13.753.683 | Unverändert | 0,0% | |
| Elmind Capital, LP | 475.750 | 475.750 | 0 | 13.439.938 | Unverändert | 0,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 462.251 | 496.259 | -34.008 | 13.058.591 | Reduziert | -6,9% | |
| Eversept Partners, LP | 406.960 | 439.177 | -32.217 | 11.496.620 | Reduziert | -7,3% | |
| BAKER BROS. ADVISORS LP | 375.000 | 375.000 | 0 | 10.593.750 | Unverändert | 0,0% | |
| D. E. Shaw & Co., Inc. | 321.157 | 260.572 | 60.585 | 9.072.685 | Aufgestockt | +23,3% | |
| Tetragon Partners GP Ltd | 221.611 | 194.612 | 26.999 | 6.260.511 | Aufgestockt | +13,9% | |
| ORBIMED ADVISORS LLC | 205.400 | 205.400 | 0 | 5.802.550 | Unverändert | 0,0% | |
| Kalehua Capital Management LLC | 198.772 | 198.772 | 0 | 5.615.309 | Unverändert | 0,0% | |
| Foresite Capital Management V, LLC | 194.125 | 0 | 194.125 | 5.484.031 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 181.946 | 248.858 | -66.912 | 5.139.974 | Reduziert | -26,9% | |
| Seven Fleet Capital Management LP | 172.731 | 55.342 | 117.389 | 4.879.651 | Aufgestockt | +212,1% | |
| CITADEL ADVISORS LLC | 168.630 | 135.069 | 33.561 | 4.763.798 | Aufgestockt | +24,8% | |
| Jones Hill Capital LP | 167.014 | 0 | 167.014 | 4.718.146 | Neu | +100,0% | |
| Octagon Capital Advisors LP | 165.000 | 671.465 | -506.465 | 4.661.250 | Reduziert | -75,4% | |
| MORGAN STANLEY | 164.323 | 248.334 | -84.011 | 4.642.125 | Reduziert | -33,8% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 157.117 | 157.117 | 0 | 4.438.555 | Unverändert | 0,0% | |
| STATE STREET CORP | 152.945 | 161.499 | -8.554 | 4.320.696 | Reduziert | -5,3% | |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 158.019 | 158.019 | 0 | 4.312.339 | Unverändert | 0,0% | |
| GOLDMAN SACHS GROUP INC | 142.929 | 160.910 | -17.981 | 4.037.745 | Reduziert | -11,2% | |
| TWO SIGMA INVESTMENTS, LP | 126.076 | 215.188 | -89.112 | 3.561.647 | Reduziert | -41,4% | |
| Alyeska Investment Group, L.P. | 125.000 | 125.000 | 0 | 3.531.250 | Unverändert | 0,0% | |
| ADAR1 Capital Management, LLC | 105.528 | 85.528 | 20.000 | 2.981.166 | Aufgestockt | +23,4% | |
| HighVista Strategies LLC | 97.866 | 162.370 | -64.504 | 2.764.715 | Reduziert | -39,7% | |
| Squarepoint Ops LLC | 96.384 | 100.359 | -3.975 | 2.722.848 | Reduziert | -4,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 89.129 | 86.801 | 2.328 | 2.517.541 | Aufgestockt | +2,7% | |
| TWO SIGMA ADVISERS, LP | 89.600 | 0 | 89.600 | 2.486.400 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 86.774 | 121.724 | -34.950 | 2.451.366 | Reduziert | -28,7% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| GENERAL ATLANTIC, L.P. | 8.031.252 | 8.031.252 | 0,0% | 226.882.869 | 13,76 |
| FMR LLC | 6.284.472 | 6.399.158 | -1,8% | 177.536.335 | 10,77 |
| Foresite Capital Management IV, LLC | 4.778.581 | 4.778.581 | 0,0% | 134.994.913 | 8,19 |
| venBio Partners LLC | 4.639.304 | 4.639.304 | 0,0% | 131.060.338 | 7,95 |
| VIKING GLOBAL INVESTORS LP | 3.653.310 | 3.653.310 | 0,0% | 103.206.008 | 6,26 |
| EQT Fund Management S.a r.l. | 3.424.609 | 3.424.609 | 0,0% | 96.745.204 | 5,87 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.126.042 | 3.126.042 | 0,0% | 88.310.687 | 5,36 |
| Bain Capital Life Sciences Investors, LLC | 2.675.509 | 2.802.081 | -4,5% | 75.583.129 | 4,58 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.118.900 | 1.905.793 | +11,2% | 59.858.926 | 3,63 |
| Commodore Capital LP | 1.918.970 | 1.889.445 | +1,6% | 54.210.903 | 3,29 |
| Novo Holdings A/S | 1.750.000 | 1.750.000 | 0,0% | 49.437.500 | 3,00 |
| Saturn V Capital Management LP | 1.201.402 | 1.140.033 | +5,4% | 33.939.606 | 2,06 |
| Point72 Asset Management, L.P. | 1.007.016 | 711.625 | +41,5% | 28.448.202 | 1,73 |
| Cormorant Asset Management, LP | 1.000.000 | 1.083.000 | -7,7% | 28.250.000 | 1,71 |
| Sofinnova Investments, Inc. | 818.328 | 745.169 | +9,8% | 23.117.766 | 1,40 |
| 5AM Venture Management, LLC | 797.600 | 797.600 | 0,0% | 22.532.200 | 1,37 |
| Polar Capital Holdings Plc | 781.016 | 237.962 | +228,2% | 22.063.702 | 1,34 |
| BlackRock, Inc. | 757.213 | 708.558 | +6,9% | 21.391.267 | 1,30 |
| Soleus Capital Management, L.P. | 702.052 | 702.052 | 0,0% | 19.832.969 | 1,20 |
| Rock Springs Capital Management LP | 645.533 | 623.402 | +3,6% | 18.236.307 | 1,11 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 111 | 59,5 | 1.667 |
| 31.12.2025 | ✓ | 106 | 59,7 | 1.629 |
| 30.09.2025 | ✓ | 84 | 58,0 | 1.427 |
| 30.06.2025 | ✓ | 60 | 45,0 | 779 |
| 31.03.2025 | ✓ | 52 | 45,3 | 710 |
| 31.12.2024 | ✓ | 54 | 44,7 | 848 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Elmind Capital, LP | 475.750 | 13.202.063 |
| Eversept Partners, LP | 439.177 | 12.187.162 |
| ORBIMED ADVISORS LLC | 205.400 | 5.699.850 |
| Kalehua Capital Management LLC | 198.772 | 5.515.923 |
| HighVista Strategies LLC | 162.370 | 4.505.768 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 121.724 | 3.377.841 |
| Squarepoint Ops LLC | 100.359 | 2.784.962 |
| TWO SIGMA ADVISERS, LP | 89.600 | 2.486.400 |
| Trexquant Investment LP | 84.353 | 2.340.796 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 83.947 | 2.329.529 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.126.042 | 683.578 | +28.0 % | 86.747.666 |
| BlackRock, Inc. | 708.558 | 294.141 | +71.0 % | 19.662.485 |
| Ikarian Capital, LLC | 486.856 | 276.691 | +131.7 % | 13.510.255 |
| Saturn V Capital Management LP | 1.140.033 | 253.701 | +28.6 % | 31.635.916 |
| D. E. Shaw & Co., Inc. | 260.572 | 237.686 | +1038.6 % | 7.230.873 |
| TWO SIGMA INVESTMENTS, LP | 215.188 | 204.581 | +1928.7 % | 5.971.467 |
| Patient Square Capital LP | 542.696 | 197.315 | +57.1 % | 15.059.814 |
| Point72 Asset Management, L.P. | 711.625 | 192.244 | +37.0 % | 19.747.594 |
| MORGAN STANLEY | 248.334 | 190.071 | +326.2 % | 6.891.270 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.905.793 | 171.050 | +9.9 % | 52.885.757 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Commodore Capital LP | 1.889.445 | -529.031 | -21.9 % | 52.432.099 |
| Bain Capital Life Sciences Investors, LLC | 2.802.081 | -379.194 | -11.9 % | 77.757.748 |
| Cormorant Asset Management, LP | 1.083.000 | -280.200 | -20.6 % | 30.053.250 |
| BALYASNY ASSET MANAGEMENT L.P. | 496.259 | -129.499 | -20.7 % | 13.771.187 |
| GREAT POINT PARTNERS LLC | 82.800 | -72.305 | -46.6 % | 2.297.700 |
| SPHERA FUNDS MANAGEMENT LTD. | 63.953 | -55.453 | -46.4 % | 1.774.696 |
| Octagon Capital Advisors LP | 671.465 | -51.130 | -7.1 % | 18.633.154 |
| Logos Global Management LP | 100.000 | -50.000 | -33.3 % | 2.775.000 |
| Kynam Capital Management, LP | 640.395 | -34.605 | -5.1 % | 17.770.961 |
| Polar Capital Holdings Plc | 237.962 | -26.731 | -10.1 % | 6.603.446 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 15.05.2026 | HALVORSEN OLE ANDREAS | Passiv (13G/A) | 5,60 % | 3.653.310 | Neu | |
| 15.05.2026 | Viking Global Opportunities Portfolio GP LLC | Passiv (13G/A) | 5,60 % | 3.653.310 | -1,40 pp | |
| 15.05.2026 | Viking Global Opportunities Illiquid Investments Sub-Master LP | Passiv (13G/A) | 5,60 % | 3.653.310 | -1,40 pp | |
| 15.05.2026 | Shabet Rose Sharon | Passiv (13G/A) | 5,60 % | 3.653.310 | Neu | |
| 15.05.2026 | Viking Global Opportunities Parent GP LLC | Passiv (13G/A) | 5,60 % | 3.653.310 | -1,40 pp | |
| 15.05.2026 | VIKING GLOBAL INVESTORS LP | Passiv (13G/A) | 5,60 % | 3.653.310 | Neu | |
| 15.05.2026 | Viking Global Opportunities GP LLC | Passiv (13G/A) | 5,60 % | 3.653.310 | -1,40 pp | |
| 17.02.2026 | Bain Capital Life Sciences Opportunities III, LP | Passiv (13G/A) | 1,50 % | 993.314 | -0,30 pp | |
| 17.02.2026 | Bain Capital Life Sciences Fund, L.P. | Passiv (13G/A) | 2,50 % | 1.640.817 | -0,50 pp | |
| 17.02.2026 | BCIP Life Sciences Associates, LP | Passiv (13G/A) | 0,30 % | 167.950 | 0,00 pp | |
| 14.11.2025 | Bain Capital Life Sciences Opportunities III, LP | Passiv (13G/A) | 1,80 % | 1.122.481 | -0,50 pp | |
| 14.11.2025 | Bain Capital Life Sciences Fund, L.P. | Passiv (13G/A) | 3,00 % | 1.867.629 | -0,80 pp | |
| 14.11.2025 | BCIP Life Sciences Associates, LP | Passiv (13G/A) | 0,30 % | 191.165 | -0,10 pp | |
| 14.08.2025 | Bong Y. Koh | Passiv (13G/A) | 3,80 % | 2.047.620 | Neu | |
| 14.08.2025 | Venrock Healthcare Capital Partners III, L.P. | Passiv (13G/A) | 3,80 % | 2.047.620 | -2,70 pp | |
| 14.08.2025 | VHCP Co-Investment Holdings III, LLC | Passiv (13G/A) | 3,80 % | 2.047.620 | -2,70 pp | |
| 14.08.2025 | VHCP Management III, LLC | Passiv (13G/A) | 3,80 % | 2.047.620 | -2,70 pp | |
| 14.08.2025 | VHCP Management EG, LLC | Passiv (13G/A) | 3,80 % | 2.047.620 | -2,70 pp | |
| 14.08.2025 | Nimish Shah | Passiv (13G/A) | 3,80 % | 2.047.620 | Neu | |
| 14.08.2025 | Venrock Healthcare Capital Partners EG, L.P. | Passiv (13G/A) | 3,80 % | 2.047.620 | -2,70 pp | |
| 14.02.2024 | Shah, Nimish | Passiv (13G/A) | 6,50 % | 3.395.606 | +0,40 pp | |
| 14.02.2024 | Koh, Bong | Passiv (13G/A) | 6,50 % | 3.395.606 | +0,40 pp | |
| 14.02.2024 | Venrock Healthcare Capital Partners EG, L.P. | Passiv (13G/A) | 6,50 % | 3.395.606 | +0,40 pp | |
| 14.02.2024 | VHCP Management III, LLC | Passiv (13G/A) | 6,50 % | 3.395.606 | +0,40 pp | |
| 14.02.2024 | VHCP Co-Investment Holdings III, LLC | Passiv (13G/A) | 6,50 % | 3.395.606 | +0,40 pp | |
| 14.02.2024 | Venrock Healthcare Capital Partners III, L.P. | Passiv (13G/A) | 6,50 % | 3.395.606 | +0,40 pp | |
| 14.02.2024 | VHCP Management EG, LLC | Passiv (13G/A) | 6,50 % | 3.395.606 | +0,40 pp | |
| 14.02.2024 | O. Andreas Halvorsen | Passiv (13G/A) | 7,00 % | 3.656.923 | -2,70 pp | |
| 14.02.2024 | Viking Global Opportunities Parent GP LLC | Passiv (13G/A) | 7,00 % | 3.656.923 | -2,70 pp | |
| 14.02.2024 | Viking Global Opportunities Illiquid Investments Sub-Master LP | Passiv (13G/A) | 7,00 % | 3.656.923 | -2,70 pp | |
| 14.02.2024 | Viking Global Opportunities Portfolio GP LLC | Passiv (13G/A) | 7,00 % | 3.656.923 | -2,70 pp | |
| 14.02.2024 | Viking Global Opportunities GP LLC | Passiv (13G/A) | 7,00 % | 3.656.923 | -2,70 pp | |
| 14.02.2024 | Rose S. Shabet | Passiv (13G/A) | 7,00 % | 3.656.923 | -2,70 pp | |
| 14.02.2024 | David C. Ott | Passiv (13G/A) | 7,00 % | 3.656.923 | -2,70 pp | |
| 14.02.2024 | Viking Global Investors LP | Passiv (13G/A) | 7,00 % | 3.656.923 | -2,70 pp | |
| 13.02.2024 | Foresite Capital Management IV, LLC (“FCM IV”) | Passiv (13G/A) | 7,80 % | 4.038.842 | -2,40 pp | |
| 13.02.2024 | Foresite Capital Fund V, L.P. (“FCF V”) | Passiv (13G/A) | Ausstieg | 0 | -2,10 pp | |
| 13.02.2024 | Foresite Capital Fund IV, L.P. (“FCF IV”) | Passiv (13G/A) | 7,80 % | 4.038.842 | -2,40 pp | |
| 13.02.2024 | James Tananbaum (“Tananbaum”) | Passiv (13G/A) | 7,80 % | 4.038.842 | -4,50 pp | |
| 13.02.2024 | Foresite Capital | Passiv (13G/A) | Ausstieg | 0 | Neu |
Stammdaten
Pharvaris N.V. ist ein Biopharmaunternehmen im klinischen Stadium, das sich der Entdeckung, Entwicklung und Markteinführung von Behandlungen für seltene Krankheiten widmet. Sein primäres Pipeline-Asset, PHA121, ist ein kleines Molekül-Bradykinin-B2-Rezeptor-Antagonist, das sich derzeit in Phase-II-Klinischen Studien für hereditäres Angioödem (HAE) befindet. Darüber hinaus entwickelt das Unternehmen PHVS416, eine schnellwirkende, On-Demand-Weichkapsel zur Linderung akuter HAE-Anfälle, die sich auch in der Phase-2-Entwicklung befindet. Ein dritter Kandidat, PHVS719, eine Retardtablette zur Prophylaxe, die darauf abzielt, HAE-Episoden zu verhindern, macht Fortschritte in Phase-1-Studien. Gegründet 2015 und mit Sitz in Leiden, Niederlande, ist Pharvaris in den Niederlanden, der Schweiz und den Vereinigten Staaten tätig.
Unternehmen & Branche
| Name | Pharvaris N.V. |
|---|---|
| Ticker | PHVS |
| CIK | 0001830487 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,18 Mrd. USD |
| Beta | -2,47 |
| Dividendenrendite | 0,00 % |
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance »